💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Sai Life Sciences Limited is an India-based contract research, development, and manufacturing organization (CRO/CDMO). The Company carries out contract research and manufacturing activities for customers engaged in pharmaceutical and biotechnology industries. It is engaged in…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, priced for perfection.
SAI LIFE SCIENCES LIMITED is scored on the pharma / healthcare framework. It keeps a healthy 15.6% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.46× reported profit. Free cash flow is worth about 0.3% of its market value.
Over the last 3 years revenue compounded at 22%/yr and profit at 227%/yr. Book value itself has compounded 41%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 14.1%. In the latest quarter profit fell 30% versus the prior quarter.
At 109× earnings, the stock sits at the 81st percentile of its own 1.9-year range — the expensive end of where it has historically traded. Today's price already implies ~31%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 100.79 | — | — |
| P/B | 14.11 | 4.1 | worse |
| EV/EBITDA | 49.14 | 19.33 | worse |
| ROE | 14.05 | — | — |
| ROCE | 18.23 | 14.41 | better |
| ROA | 8.61 | 1.64 | better |
| Quick Ratio | 1.51 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 22% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (227% vs 22%) — margin expansion is at work. The latest year saw a +105% swing — check if it's a one-off or structural.
Operating margin has expanded from 1% to 21% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 14% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 13pp across the window.
EPS has grown every year — each share earns more than the last, consistently. Profit grew faster than EPS (227% vs 210%) — share dilution is eroding per-share value. 210% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.5× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 10% QoQ — could be seasonality or a genuine slowdown.
Profit fell 30% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (15% → 13%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 1.9y median.
Promoters at 34.5% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.